Probiotic Intranasal Inhalation Administration Study Service

Unlocking Airway Microbiome Modulation with Route-Ready Preclinical Evidence

Probiotic development has traditionally centered on the gut, yet airway delivery creates a distinct opportunity to modulate microbial and immune activity in the nasal passages, sinuses, and lungs. It also creates practical challenges for both upper- and lower-airway product concepts: live-cell viability can change during aerosolization, nominal dose may not equal delivered dose, regional deposition can vary, and local inflammation may confound efficacy.

Respiratory microbiome companies, inhaled-formulation teams, and infection or immunology programs therefore need studies that connect formulation and device performance with biological outcomes. At Creative Biolabs, we provide customized preclinical intranasal and inhalation probiotic administration studies that integrate relevant animal models, delivery characterization, strain tracking, local tolerance, efficacy endpoints, and systemic safety into one decision-focused program.

Integrated Preclinical Support

Probiotic Intranasal and Inhalation Study Service Details

Our scope links administration engineering to biological interpretation, helping teams determine whether an outcome reflects the strain, the formulation, the device, the delivered dose, or the model itself.

Animal Model Selection

We advise on species, disease context, age, sex, background, inoculation or challenge conditions, and sampling schedule so the model can answer both delivery and biological questions. Common species include mice, rats, guinea pigs, and rabbits, selected according to airway anatomy, device feasibility, endpoint needs, and study intent.

Allergic Airway Disease

Allergic asthma and airway hyperresponsiveness models with BAL, cytokine, cellular, and histopathology endpoints.

Chronic Inflammation

COPD-relevant and other chronic inflammatory models suited to repeated-dose tolerance and efficacy questions.

Respiratory Infection

Influenza, bacterial pneumonia, and other fit-for-purpose pathogen challenge models with quantitative burden measurements.

Upper Airway Conditions

Sinusitis or nasal-colonization models for local retention, microbiome change, mucosal response, and tolerability.

Neuro-Immune Research

Exploratory neuroinflammatory models with direct biodistribution and mechanistic endpoints when nose-to-brain hypotheses are relevant.

Healthy-Animal Tolerance

Dose-ranging and repeated-dose designs focused on local findings, strain clearance, clinical observations, and systemic exposure.

Probiotic Administration Routes and Dose Delivery

Intranasal Instillation

Direct delivery of a defined liquid suspension to the nasal passages, with control of volume, concentration, anesthesia conditions, positioning, and aspiration risk.

Aerosol or Inhalation

Nebulizer, atomization, or dry-powder approaches for deeper airway exposure, supported by aerosol characterization and pre/post-device viability checks.

Oropharyngeal Aspiration

Placement at the oropharynx followed by aspiration into the lungs, useful when a practical liquid-delivery method is needed for lower-airway studies.

Device and Formulation Compatibility

Vehicle, excipient, osmolality, pH, and viscosity review
Viable count before and after device passage
Aerosol output, particle or droplet profile, and delivery reproducibility
Container, handling, hold-time, and administration-window controls

Dose and Schedule Design

Nominal, emitted, delivered, and recovered dose definition
Single-dose, repeated-dose, prophylactic, or therapeutic schedules
Vehicle, device, disease, and route controls
Sentinel time points for deposition, persistence, and clearance

Comprehensive Airway Probiotic Endpoints and Analysis

Deposition and Strain Recovery

Viable recovery, strain-specific qPCR, regional respiratory sampling, persistence kinetics, and clearance tracking.

Microbiome Analysis

16S rRNA gene sequencing or metagenomic analysis of nasal, lung, and intestinal communities, with study-appropriate controls.

Immunological Assays

Cytokines and chemokines in BAL, serum, or homogenates; flow cytometry; mucosal sIgA; and immune-cell infiltration.

Pathogen Burden

Culture, qPCR, plaque assay, or other validated methods for bacterial or viral burden in relevant respiratory tissues.

Histology and Gene Expression

Respiratory histopathology, immunohistochemistry, targeted qPCR, and RNA-seq for inflammation, injury, barrier, or mechanism markers.

Safety and Toxicity

Clinical observations, hematology, clinical chemistry, major-organ pathology, systemic exposure, and dissemination assessment where appropriate.

Decision value: integrated endpoint timing helps separate poor delivery or rapid clearance from true biological non-response, while local inflammation and pathology contextualize apparent efficacy signals.

Sample Information for Study Design

To prepare an accurate proposal and technically realistic administration plan, please provide the following information when available.

Probiotic Strain Details

Genus, species, strain designation, source, purity, identity method, viability data, and storage conditions.

Desired Formulation

Delivery vehicle, excipients, concentration, volume or powder mass, container, and proposed device.

Target Indication and Model

Disease or biological question, preferred species or model, pathogen details, and relevant comparator groups.

Research Objectives

Primary and secondary objectives, intended route, prophylactic or therapeutic context, and go/no-go criteria.

Key Endpoints

Deposition, inflammatory markers, microbiome change, pathogen reduction, pathology, behavior, or systemic safety needs.

Preliminary Data

Any formulation, aerosolization, in vitro, ex vivo, pilot in vivo, dose-ranging, or strain-tracking data.

Typical Study Samples

Nasal lavage or swabs, bronchoalveolar lavage fluid, lung lobes or regional lung samples, respiratory lymphoid tissues, blood or serum, major organs, and fecal samples can be collected according to the biological question and validated analysis plan.

Airway Probiotic Study Reports and Data Deliverables

Deliverable Component	Content Specifications	Development Use
Detailed Study Report	Methods, deviations, results, statistical analysis, interpretation, and conclusions.	Supports internal review and next-study planning.
Raw and Processed Data	Sequencing files, qPCR outputs, viable counts, assay values, cytometry plots, observations, and analysis-ready tables.	Enables traceability and independent analysis.
Histopathology Package	Digital images, scoring tables, and expert pathology interpretation when included.	Frames local tolerance, inflammation, and tissue response.
Administration and Recovery Summary	Formulation handling, device settings, delivered-dose records, viability checks, and regional recovery results.	Connects technical delivery performance to biological outcomes.

Project-Specific Turnaround Time

Study timing depends on formulation and device preparation, model complexity, acclimation, dosing frequency, disease induction, follow-up period, sample volume, and analytical endpoints. A short healthy-animal deposition or tolerance study will follow a different schedule from a repeated-dose disease-model program with sequencing, cytometry, and pathology.

We provide a detailed timeline with dependencies, interim review points, sample-analysis windows, and report delivery milestones in the project proposal.

1

Feasibility and Design

Confirm model, route, device, dose, groups, endpoints, and sample needs.

2

In-Life Phase

Complete acclimation, baseline work, administration, monitoring, and scheduled collections.

3

Analysis and Reporting

Finish assays, quality checks, statistics, interpretation, and report review.

Preclinical Airway Probiotic Administration Study Workflow

Our five-stage workflow adapts the supplied process into a route-specific plan with clear dose, recovery, safety, and interpretation checkpoints.

01

Consultation and Study Design

Define objectives, strain attributes, model, device, formulation, delivered-dose logic, groups, and endpoints.

02

Acclimation and Administration

Complete baseline work, device setup, viability checks, dosing, frequency controls, and administration records.

03

In-Life and Laboratory Analysis

Monitor animals; collect BAL, tissue, blood, and microbiome samples; assess deposition, recovery, inflammation, pathology, and safety.

04

Data Analysis and Interpretation

Apply prespecified statistics and integrate delivery, strain kinetics, efficacy, local tolerance, and systemic findings.

05

Reporting

Deliver quality-checked datasets, visual summaries, pathology outputs, and a detailed decision-focused report.

Mechanisms and Applications of Airway-Delivered Probiotics

Mechanistic endpoints should be matched to the strain, indication, and delivery hypothesis; no single pathway should be presumed across probiotic candidates.

01

Competitive Exclusion

Candidate strains may compete with pathogens for mucosal adhesion sites or nutrients; colonization, pathogen load, and co-localization assays help test this hypothesis.

02

Antimicrobial Activity

Bacteriocins, organic acids, hydrogen peroxide, or other products may affect pathogens, requiring strain-specific functional and in vivo confirmation.

03

Immunomodulation

Airway organisms may alter innate or adaptive responses; BAL cytokines, flow cytometry, mucosal antibodies, and histology can define response direction and magnitude.

04

Metabolic Effects

Microbial metabolites may influence epithelial, immune, or systemic physiology; targeted metabolite and host-response measurements can support causal interpretation.

05

Neuro-Immune Signaling

Exploratory intranasal programs may test olfactory, trigeminal, immune, or metabolite-mediated hypotheses, but CNS distribution must be demonstrated directly rather than assumed.

Published Data Informing Intranasal Probiotic Study Design

Respiratory probiotic priming effects on survival and bacterial load in mouse lungs. (OA Literature) — Fig.1 Mice survival rate and pulmonary *P. aeruginosa* burden. ^1,2

Recently published research evaluated two Lactobacillus blends administered intranasally before Pseudomonas aeruginosa challenge in a murine acute-pneumonia model. The image illustrates survival and pulmonary pathogen-burden results: respiratory priming improved survival and enhanced bacterial clearance, while the wider study also measured BAL leukocytes and cytokines. These findings matter for airway probiotic studies because they connect administration route and viable dose with local microbial recovery, infection outcomes, and inflammatory response rather than treating efficacy as a single endpoint.

For product teams, the study also highlights why strain persistence, dose selection, vehicle controls, and respiratory safety observations should be built into the same protocol. Creative Biolabs can translate these principles into customized intranasal or inhalation programs with device-formulation compatibility work, deposition and recovery measurements, local pathology, immunophenotyping, pathogen quantification, strain-clearance tracking, and systemic safety assessment. The resulting design helps distinguish delivery failure from biological non-response and supports clearer go/no-go decisions for respiratory microbiome candidates.

Advantages of Partnering with Creative Biolabs

A route-specific program benefits from coordinated formulation, animal, microbiology, pathology, immunology, and data-analysis expertise.

Scientist preparing an intranasal or inhalation probiotic administration study (Creative Biolabs Original)

Specialized Expertise

Experience across probiotic research, animal models, respiratory biology, microbiology, and immune analysis.

Advanced Facilities

Instrumentation and workflows for controlled administration, phenotyping, sequencing, bioanalysis, and pathology.

Customized Study Design

Flexible route, device, model, dose, schedule, control, and endpoint plans aligned with program questions.

Ethical and Compliant Research

Studies are planned and conducted under applicable animal-welfare and quality requirements.

High-Quality Data

Prespecified analysis, quality checks, traceable outputs, and integrated interpretation improve data reliability.

Collaborative Delivery

Transparent communication, milestone reviews, and active scientific discussion throughout the project.

Development-Focused Decisions

Integrated delivery, efficacy, tolerance, and clearance evidence helps teams prioritize candidates and plan the next preclinical package with greater confidence.

Recommended Services for Airway Probiotic Programs

Extend route feasibility into indication-specific efficacy, safety, and broader preclinical planning with complementary Creative Biolabs services.

Probiotics Preclinical Animal Study Services Advanced Infectious Disease Animal Model Service for Probiotic Efficacy Evaluation Advanced Chronic Inflammatory Animal Model Service for Probiotic Efficacy Evaluation Probiotics Preclinical Safety & Efficacy Assessment Services

Frequently Asked Questions

Mice and rats are frequently used because they support well-established respiratory infection, allergy, inflammation, and safety models. Depending on airway anatomy, device compatibility, sample-volume requirements, and the development question, guinea pigs, rabbits, or another appropriate species may be considered.

We build viability checks around formulation preparation, hold time, device passage, and dosing. Depending on the route, the plan may compare loaded, emitted, and recovered viable counts and may evaluate the effects of excipients, shear, atomization, drying, or environmental exposure.

Yes. We can evaluate the feasibility of adapting a model around the indication, host background, challenge organism or inflammatory trigger, delivery route, dosing schedule, and proposed endpoints. Pilot work may be recommended when key model or administration variables are not yet established.

The study can include pre- and post-device viable counts, regional airway recovery, early deposition time points, strain-specific qPCR, and clearance kinetics alongside efficacy endpoints. This combination shows whether a viable dose reached the target site before biological response is interpreted.

Programs may include clinical observations, respiratory signs, body weight, BAL cytology, cytokines, lung histopathology, hematology, clinical chemistry, major-organ pathology, systemic exposure, dissemination, and strain clearance. The final panel is tailored to the strain, route, dose, duration, and study intent.

Other Resources

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic strain products brochure (Creative Biolabs Original)

Probiotic Strain Products for NGP Research - Brochure

Small-scale probiotic production brochure (Creative Biolabs Original)

Custom Small-scale Probiotic Production - Brochure

Live biotherapeutics research video (Creative Biolabs Original)

Live Biotherapeutics - Creative Biolabs - Video

References

Fangous, Marie-Sarah, et al. "Priming with intranasal lactobacilli prevents Pseudomonas aeruginosa acute pneumonia in mice." BMC Microbiology 21.1 (2021): 195. https://doi.org/10.1186/s12866-021-02254-7
Distributed under Open Access license CC BY 4.0, without modification.